On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE: PFE) as his final trade.
Pfizer announced that a Phase 3 study of the antibody-drug conjugate Adcetris (brentuximab vedotin) combined with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo.
Jim Lebenthal of Cerity Partners picked Alphabet Inc. (NASDAQ: GOOG)(NASDAQ: GOOGL). "I think this one is coming back. The failed image ...